USPH Quote, Financials, Valuation and Earnings

Encompass Health has a net margin of 6.97% compared to US Physical Therapy's net margin of 10.41%. US Physical Therapy's return on equity of 4.62% beat Encompass Health's return on equity of 18.4%.

US Physical Therapy has a consensus price target of $106.00, signalling upside risk potential of 41.35%. On the other hand Encompass Health has an analysts' consensus of $131.27 which suggests that it could grow by 8.58%. Given that US Physical Therapy has higher upside potential than Encompass Health, analysts believe US Physical Therapy is more attractive than Encompass Health.

US Physical Therapy has a beta of 1.438, which suggesting that the stock is 43.783% more volatile than S&P 500. In comparison Encompass Health has a beta of 0.930, suggesting its less volatile than the S&P 500 by 7.02%.

US Physical Therapy has a quarterly dividend of $0.45 per share corresponding to a yield of 2.37%. Encompass Health offers a yield of 0.55% to investors and pays a quarterly dividend of $0.17 per share. US Physical Therapy pays 100.3% of its earnings as a dividend. Encompass Health pays out 13.78% of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but US Physical Therapy's is not.

US Physical Therapy quarterly revenues are $183.8M, which are smaller than Encompass Health quarterly revenues of $1.5B. US Physical Therapy's net income of $12.8M is lower than Encompass Health's net income of $151.5M. Notably, US Physical Therapy's price-to-earnings ratio is 34.40x while Encompass Health's PE ratio is 24.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for US Physical Therapy is 1.62x versus 2.24x for Encompass Health. Usually stocks with elevated PS ratios are considered overvalued.

Pediatrix Medical Group has a net margin of 6.97% compared to US Physical Therapy's net margin of 4.52%. US Physical Therapy's return on equity of 4.62% beat Pediatrix Medical Group's return on equity of -10.7%.

US Physical Therapy has a consensus price target of $106.00, signalling upside risk potential of 41.35%. On the other hand Pediatrix Medical Group has an analysts' consensus of $17.14 which suggests that it could grow by 21.15%. Given that US Physical Therapy has higher upside potential than Pediatrix Medical Group, analysts believe US Physical Therapy is more attractive than Pediatrix Medical Group.

US Physical Therapy has a beta of 1.438, which suggesting that the stock is 43.783% more volatile than S&P 500. In comparison Pediatrix Medical Group has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.315%.

US Physical Therapy has a quarterly dividend of $0.45 per share corresponding to a yield of 2.37%. Pediatrix Medical Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. US Physical Therapy pays 100.3% of its earnings as a dividend. Pediatrix Medical Group pays out -- of its earnings as a dividend.

US Physical Therapy quarterly revenues are $183.8M, which are smaller than Pediatrix Medical Group quarterly revenues of $458.4M. US Physical Therapy's net income of $12.8M is lower than Pediatrix Medical Group's net income of $20.7M. Notably, US Physical Therapy's price-to-earnings ratio is 34.40x while Pediatrix Medical Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for US Physical Therapy is 1.62x versus 0.60x for Pediatrix Medical Group. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute has a net margin of 6.97% compared to US Physical Therapy's net margin of -18.76%. US Physical Therapy's return on equity of 4.62% beat The Oncology Institute's return on equity of -340.01%.

US Physical Therapy has a consensus price target of $106.00, signalling upside risk potential of 41.35%. On the other hand The Oncology Institute has an analysts' consensus of $7.00 which suggests that it could grow by 119.44%. Given that The Oncology Institute has higher upside potential than US Physical Therapy, analysts believe The Oncology Institute is more attractive than US Physical Therapy.

US Physical Therapy has a beta of 1.438, which suggesting that the stock is 43.783% more volatile than S&P 500. In comparison The Oncology Institute has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

US Physical Therapy has a quarterly dividend of $0.45 per share corresponding to a yield of 2.37%. The Oncology Institute offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. US Physical Therapy pays 100.3% of its earnings as a dividend. The Oncology Institute pays out -- of its earnings as a dividend.

US Physical Therapy quarterly revenues are $183.8M, which are larger than The Oncology Institute quarterly revenues of $104.4M. US Physical Therapy's net income of $12.8M is higher than The Oncology Institute's net income of -$19.6M. Notably, US Physical Therapy's price-to-earnings ratio is 34.40x while The Oncology Institute's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for US Physical Therapy is 1.62x versus 0.60x for The Oncology Institute. Usually stocks with elevated PS ratios are considered overvalued.